For patients with NHL, G-CSF SD plus a new CXCR4 antagonist YF-H-2015005 also significantly increased the number of total CD34+ cells collected and the successful rate of achieving optimal mobilization target. Here, CXCR4 is linked to non-Hodgkin lymphoma.